Ditchcarbon
  • Contact
  1. Organizations
  2. Tillotts Pharma AG
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 14 days ago

Tillotts Pharma AG Sustainability Profile

Company website

Tillotts Pharma AG, headquartered in Switzerland (CH), is a prominent player in the pharmaceutical industry, specialising in gastrointestinal therapies. Founded in 2000, the company has established itself as a leader in developing innovative treatments for conditions such as inflammatory bowel disease and irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Tillotts Pharma is renowned for its unique product offerings, including the well-regarded 5-ASA compound, which sets it apart in the market. The company’s commitment to research and development has led to significant milestones, enhancing its reputation for quality and efficacy. Recognised for its contributions to patient care, Tillotts Pharma AG continues to solidify its market position through strategic partnerships and a focus on unmet medical needs, making it a trusted name in gastrointestinal health.

DitchCarbon Score

How does Tillotts Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

16

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Tillotts Pharma AG's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

11%

Let us know if this data was useful to you

Tillotts Pharma AG's reported carbon emissions

Tillotts Pharma AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zeria Pharmaceutical Co., Ltd., which may influence its climate-related initiatives and reporting practices. As of now, Tillotts Pharma AG has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, it is increasingly important for companies like Tillotts Pharma AG to adopt robust climate commitments and transparent emissions reporting to align with global sustainability goals. The cascading of data and initiatives from Zeria Pharmaceutical Co., Ltd. may provide a framework for future climate action, but specific details on emissions and reduction strategies remain unavailable at this time.

How Carbon Intensive is Tillotts Pharma AG's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Tillotts Pharma AG's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Tillotts Pharma AG's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Tillotts Pharma AG is in CH, which has a very low grid carbon intensity relative to other regions.

Tillotts Pharma AG's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Tillotts Pharma AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Tillotts Pharma AG's Emissions with Industry Peers

Ferring

IN
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 15 days ago

Shire plc

IE
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Eisai

JP
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Viatris

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy